orforglipron vs tirzepatide Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Weight Loss Blog – Maryland

This raises the possibility that defective CFTR activity could lead to immature enterocytes with impaired nutrient absorption, a hallmark of CFTR mutations 124,125,126,127,128

Patients who tend to do well with this program typically: Have tried diet and exercise without lasting success Are in generally good overall health Do not have a history of pancreatitis, type 1 diabetes, or certain liver or kidney conditions Want structured, clinically guided support rather than a self-managed approach Are prepared for ongoing follow-up rather than a one-time treatment If you're unsure whether you qualify, that's exactly what the consultation is for, not every patient is a fit for GLP-1 therapy, and an honest evaluation upfront is part of responsible care

In a previous double-blind placebo-controlled phase II trial, 42 self-sufficient subjects (with a score of 3+ on the ALSFRS-R items for swallowing, cutting food and handling utensils, and walking) with ALS [10] received ALCAR 3 g/day and 40 received placebo in an equivalent dose, and were followed for 12 months or until death [11]

Compared to daily dosing for other medications, the convenience of weekly dosing further enhances its appeal

GI: gastrointestinal